Patent Term Extended Under 35 U.S.C.   156(e)(2)


An order granting an interim extension of the term of the following
patent was issued on November 9, 1998.

SCM Chemicals, Inc., the owner of record in the Patent and Trademark
Office (PTO) of U.S. Patent No. 4,209,430, filed an application for
patent term extension under 35 U.S.C.    156 on October 23, 1996
(certificate of mailing October 19, 1996), requesting an extension of
1,385 days. The original term of the patent is due to expire on November
24, 1998. The patent claims the food additive "Silvacote K," and a
method of use of the food additive "Silvacote K." "Silvacote K" was
approved by the Food and Drug Administration for commercial marketing or
use on August 31, 1996. In accordance with the limitation of 35 U.S.C.
 156(g)(6)(C), applicant is entitled to an extension of at least two
years.

The initial PTO review of the application to date indicates that the
subject patent would be eligible for extension of the patent term under
35 U.S.C.    156. A final determination of the length of the extension
of the patent term and issuance of a patent term extension certificate
cannot be made until a final determination of the length of the
regulatory review period is made. Since the original term of the patent
would expire before a certificate of patent term extension can be
issued, an interim extension of the patent term is appropriate.
An interim extension under 35 U.S.C.    156(e)(2) of the term of U.S.
Patent No. 4,209,430 has been granted for a period of one year from the
original expiration date of the patent.


               Patent Term Extended Under 35 U.S.C.   156(e)(2)

An order granting an interim extension of the term of the following
patent was issued on September 15, 1998.

On January 8, 1997, Merck & Co., Inc., the owner of record in the Patent
and Trademark Office (PTO) of U.S. Patent No. 4,199,569, filed an
application for patent term extension under 35 U.S.C.    156 based upon
the regulatory review of the human drug product STROMECTOL
(ivermectin). The human drug product STROMECTOL    was approved for
commercial marketing or use under section 505 of the Federal Food, Drug
and Cosmetic Act by the Food and Drug Administration on November 22,
1996. The original term of the patent expired on October 3, 1997, but an
interim extension under 35 U.S.C. Z   156(e)(2) has been granted for a
period of one year, i.e, until October 3, 1998. The patent claims the
active ingredient ivermectin in the human drug product STROMECTOL    and
a method of use of ivermectin. An extension of 1,026 days is requested.
PTO review of the application to date indicates that the subject patent
would be eligible for extension of the patent term under 35 U.S.C.
156. A final determination of the length of the extension of the patent
term and issuance of a patent term extension certificate cannot be made
until a final determination of the length of the regulatory review
period is made by the Food and Drug Administration. Since the term of
the patent, as already extended under 35 U.S.C.    156(e)(2), would
expire before a certificate of patent term extension can be issued, a
second interim extension of the patent term is appropriate. The rights
derived from an extension under 35 U.S.C.    156(e), including an
interim extension, are limited by 35 U.S.C.    156(b).

A second interim extension under 35 U.S.C.    156(e)(2) of the term of
U.S. Patent No. 4,199,569 is granted for a period of one year from
October 3, 1998, the expiration date of the patent, as extended by the
prior one-year interim extension under 35 U.S.C.    156(e)(2).